Newark-based Botox Company Files For IPO

Revance Therapeutics Inc. filed paperwork with the SEC on Thursday to raise $86 million through an initial public offering. 

The company is a clinical-stage biopharmaceutical business based in Newark, California that makes an enhanced botulinum toxin, which is also known as Botox. Its staff is researching ways to make botox a cream instead of an injection, according to its website.

The company is raising money to finance trials of this and other products. It raised $33 million during a round of series E financing back in April 2013.

The company plans to list on NASDAQ with the symbol RVNC. Cowen & Company as well as Piper Jaffray are co-book runners on the deal.

Revance Therapeutics Inc. was founded in 1999.